Royalty Pharma PLC has a consensus price target of $50.75, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Goldman Sachs, and Morgan Stanley on February 20, 2024, February 20, 2024, and November 9, 2023. With an average price target of $49.67 between JP Morgan, Goldman Sachs, and Morgan Stanley, there's an implied 63.11% upside for Royalty Pharma PLC from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/20/2024 | RPRX | Buy Now | Royalty Pharma | $30.45 | 37.93% | JP Morgan | Chris Schott | $45 → $42 | Maintains | Overweight | Get Alert |
02/20/2024 | RPRX | Buy Now | Royalty Pharma | $30.45 | 64.2% | Goldman Sachs | Chris Shibutani | $56 → $50 | Maintains | Buy | Get Alert |
11/09/2023 | RPRX | Buy Now | Royalty Pharma | $30.45 | 87.19% | Morgan Stanley | Terence Flynn | $54 → $57 | Maintains | Overweight | Get Alert |
10/11/2023 | RPRX | Buy Now | Royalty Pharma | $30.45 | 77.34% | Morgan Stanley | Terence Flynn | $53 → $54 | Maintains | Overweight | Get Alert |
08/09/2023 | RPRX | Buy Now | Royalty Pharma | $30.45 | 74.06% | Morgan Stanley | Terence Flynn | $52 → $53 | Maintains | Overweight | Get Alert |
07/11/2023 | RPRX | Buy Now | Royalty Pharma | $30.45 | 70.77% | Morgan Stanley | Terence Flynn | $52 → $52 | Reiterates | Overweight → Overweight | Get Alert |
05/10/2023 | RPRX | Buy Now | Royalty Pharma | $30.45 | 70.77% | Morgan Stanley | Terence Flynn | $50 → $52 | Maintains | Overweight | Get Alert |
04/10/2023 | RPRX | Buy Now | Royalty Pharma | $30.45 | 64.2% | Morgan Stanley | Terence Flynn | $48 → $50 | Maintains | Overweight | Get Alert |
04/06/2023 | RPRX | Buy Now | Royalty Pharma | $30.45 | 97.04% | Tigress Financial | Ivan Feinseth | $57 → $60 | Reiterates | → Buy | Get Alert |
02/16/2023 | RPRX | Buy Now | Royalty Pharma | $30.45 | 57.64% | UBS | Ashwani Verma | $51 → $48 | Maintains | Buy | Get Alert |
12/06/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 67.49% | Morgan Stanley | Terence Flynn | $54 → $51 | Maintains | Overweight | Get Alert |
11/09/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 77.34% | Morgan Stanley | Terence Flynn | $51 → $54 | Maintains | Overweight | Get Alert |
10/18/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 70.77% | JP Morgan | Chris Schott | $50 → $52 | Maintains | Overweight | Get Alert |
08/08/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 67.49% | Morgan Stanley | Terence Flynn | $48 → $51 | Maintains | Overweight | Get Alert |
07/14/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 87.19% | Tigress Financial | Ivan Feinseth | $52 → $57 | Maintains | Buy | Get Alert |
06/14/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 54.35% | UBS | Ashwani Verma | → $47 | Initiates | → Buy | Get Alert |
05/13/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 74.06% | Scotiabank | Adam Buckham | → $53 | Initiates | → Outperform | Get Alert |
04/27/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 83.91% | Goldman Sachs | Chris Shibutani | → $56 | Initiates | → Buy | Get Alert |
04/14/2022 | RPRX | Buy Now | Royalty Pharma | $30.45 | 64.2% | JP Morgan | Chris Schott | → $50 | Upgrade | Neutral → Overweight | Get Alert |
The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by JP Morgan on February 20, 2024. The analyst firm set a price target for $42.00 expecting RPRX to rise to within 12 months (a possible 37.93% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Royalty Pharma (NASDAQ: RPRX) was provided by JP Morgan, and Royalty Pharma maintained their overweight rating.
The last upgrade for Royalty Pharma PLC happened on April 14, 2022 when JP Morgan raised their price target to $50. JP Morgan previously had a neutral for Royalty Pharma PLC.
There is no last downgrade for Royalty Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on February 20, 2024 so you should expect the next rating to be made available sometime around February 20, 2025.
While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $45.00 to $42.00. The current price Royalty Pharma (RPRX) is trading at is $30.45, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.